Kenvue (KVUE) Appoints New Asia Pacific Head to Drive Regional Growth

Kenvue Inc. (NYSE:KVUE) is one of the 12 best consumer goods stocks billionaires are quietly buying. On June 24, the company confirmed the departure of Asia Pacific president Ellie Bing Xie, effective July 14. However, he will remain with the company through August 8, 2025, to assist in the transition.

Kenvue (KVUE) Appoints New Asia Pacific Head to Drive Regional Growth

A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.

The company has already appointed Anindya (Andy) Dasgupta to take over as the Group President of Asia Pacific, effective July 14, 2025. He joins the company as a 30-year global consumer products industry veteran. The Asia Pacific Group contributed about $3 billion in net sales for Kenvue in 2024.

Dasgupta joins the company with vast experience in health, nutrition, and food and beverage sectors across emerging and developed markets. He also brings extensive experience in commercial strategy, sales, marketing, and business development.

Kenvue Inc. (NYSE:KVUE) is a global consumer health company that develops, manufactures, and sells over-the-counter (OTC) medicines, personal care products, and other healthcare products. It is known for iconic brands like Tylenol, Neutrogena, Listerine, and Johnson’s, among others.

While we acknowledge the potential of Kenvue Inc. (NYSE:KVUE) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KVUE and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: Top 10 Nuclear Energy Stocks to Invest in for the Next Decade and 10 Best Healthcare Penny Stocks to Buy According to Analysts.

Disclosure: None. This article is originally published at Insider Monkey.